Evidence map›Paper›PMID 26519490›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2016

Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.

N I Cherny, R Sullivan, U Dafni, J M Kerst, A Sobrero, C Zielinski, E G E de Vries, M J Piccart

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

N I ChernyDepartment of Medical Oncology, Cancer Pain and Palliative Medicine Service, Shaare Zedek Medical Center, Jerusalem, Israel chernyn@netvision.net.il.
R SullivanKings Health Partners Integrated Cancer Centre, King's College London, Institute of Cancer Policy, London, UK.
U DafniDivision of Public Health, Department of Nursing, Laboratory of Biostatistics, University of Athens, Athens, Greece.
J M KerstDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
A SobreroDepartment of Medical Oncology, Ospedale San Martino, Genova, Italy.
C ZielinskiDivision of Oncology, Medical University Vienna, Vienna, Austria.
E G E de VriesDepartment of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.
M J PiccartDepartment of Medicine, Université Libre de Bruxelles, Jules Bordet Institute, Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HumansNeoplasmsOutcome Assessment, Health Care

Identifiers

PMID26519490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.